Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III first-line immunotherapy plus platinum-based chemotherapy study in stage IV non-small cell lung cancer
CTR20180636Phase 3Active
- Sponsor
- MedImmune
- Start
- Oct 2020
- Modality
- PD-1/PD-L1 Inhibitors → Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of durvalumab, tremelimumab in non-small cell lung cancer (NSCLC), sponsored by MedImmune. Started Oct 2020; status: active.
02
Drugs
durvalumabtremelimumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on CTR20180636.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180636.